Discriminating Different Classes of Toxicants by Transcript Profiling-0

<p><b>Copyright information:</b></p><p>Taken from "Discriminating Different Classes of Toxicants by Transcript Profiling"</p><p>Environmental Health Perspectives 2004;112(12):1236-1248.</p><p>Published online 1 Jul 2004</p><p>PMCID:PMC1277117.</p><p>This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original DOI.</p

Discriminating Different Classes of Toxicants by Transcript Profiling-1

<p><b>Copyright information:</b></p><p>Taken from "Discriminating Different Classes of Toxicants by Transcript Profiling"</p><p>Environmental Health Perspectives 2004;112(12):1236-1248.</p><p>Published online 1 Jul 2004</p><p>PMCID:PMC1277117.</p><p>This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original DOI.</p

Discriminating Different Classes of Toxicants by Transcript Profiling-2

<p><b>Copyright information:</b></p><p>Taken from "Discriminating Different Classes of Toxicants by Transcript Profiling"</p><p>Environmental Health Perspectives 2004;112(12):1236-1248.</p><p>Published online 1 Jul 2004</p><p>PMCID:PMC1277117.</p><p>This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original DOI.</p

Discriminating Different Classes of Toxicants by Transcript Profiling-3

<p><b>Copyright information:</b></p><p>Taken from "Discriminating Different Classes of Toxicants by Transcript Profiling"</p><p>Environmental Health Perspectives 2004;112(12):1236-1248.</p><p>Published online 1 Jul 2004</p><p>PMCID:PMC1277117.</p><p>This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original DOI.</p

Treatment-induced RNA and gene expression changes.

<p>(<b>A</b>) Total number of RNA state changes (up- or downregulation) in human hepatocytes treated with aleglitazar, tesaglitazar or Pio/Feno. (<b>B</b>) Unique and shared gene expression following treatment with aleglitazar, tesaglitazar or Pio/Feno.</p

Clustering of the hypotheses into broader biologic processes/pathways.

<p>Numbers (in the boxes) indicate the number of genes/hypotheses in molecular pathway clusters.</p

Molecular pathways modulated in response to treatment with aleglitazar, tesaglitazar or Pio/Feno.

<p>Number of RNA expression changes observed following treatment with aleglitazar, tesaglitazar or Pio/Feno. Of the 2,000 unique mechanisms represented in the knowledgebase, 280 were considered statistically significant in at least one treatment condition and are designated as “hypotheses”.</p

Insulin signaling and biologic response-associated RNA changes and inferred signaling pathways.

<p>(<b>A</b>) Observed RNA state changes related to insulin signaling and biologic processes inferred to increase or decrease upon treatment with aleglitazar, tesaglitazar or Pio/Feno. See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035012#pone-0035012-g002" target="_blank"><i>Figure 2A</i></a> for treatment dosages. (<b>B</b>) Molecular signaling pathway that could lead to changes in insulin signaling to decrease cellular proliferation. Depiction is based on data derived from treatment with the medium concentration of aleglitazar. Numbers in the blue or yellow boxes indicate the number of gene expression state changes that support the inference: negative numbers indicate an inferred decrease and positive numbers indicate an inferred increase. Numbers in the green or red boxes indicate the log fold change. AMP, adenosine monophosphate; CDK, cyclin-dependent kinase; Med, medium.</p

PPAR-α signaling, lipid metabolism-associated RNA changes and inferred signaling pathways.

<p>(<b>A</b>) Observed RNA state changes and Causal Network Modeling–based predictions of PPAR-α signaling and lipid metabolism upon treatment with aleglitazar, tesaglitazar or Pio/Feno. See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035012#pone-0035012-g002" target="_blank"><i>Figure 2A</i></a> for treatment dosages. “Bile duct ligation” is known as a “proxy” hypothesis and describes the finding that changes in gene expression observed in the current experiments are consistent with gene expression modulations in other experiments where bile duct ligation was the perturbation. Similarly “Response to osmotic stress”, “Reponse to shear stress”, “Corticotropin”, “Response to DNA damage stimulus”, “shear stress” and “Response to stress-inducing agents” (e.g. nelfinavir) are also proxy hypotheses. (<b>B</b>) Molecular signaling pathways, predicted by RNA state changes shown in panel A, that could lead to changes in lipid parameters. Depiction is based on data derived from treatment with the medium concentration of aleglitazar. Numbers in the blue or yellow boxes indicate the number of gene expression state changes that support the inference: negative numbers indicate an inferred decrease and positive numbers indicate an inferred increase. Numbers in the green or red boxes indicate the log fold change. HDL, high-density lipoprotein; LDL, low-density lipoprotein; Med, medium; TG, triglycerides.</p

Cellular stress response-associated RNA changes and inferred signaling pathways.

<p>(<b>A</b>) Biologic processes associated with the cellular stress response inferred to increase or decrease upon treatment with aleglitazar, tesaglitazar or Pio/Feno. See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035012#pone-0035012-g002" target="_blank"><i>Figure 2A</i></a> for treatment dosages. As in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035012#pone-0035012-g005" target="_blank"><i>Figure 5A</i></a>, proxy hypotheses are shown. (<b>B</b>) Molecular signaling pathway, predicted by RNA state changes shown in panel A, that could lead to changes in the stress response. Numbers in the blue or yellow boxes indicate the number of gene expression state changes that support the inference: negative numbers indicate an inferred decrease and positive numbers indicate an inferred increase. Numbers in the green or red boxes indicate the log fold change. * Denotes genes/pathways responsive to the agent cited. ER, endoplasmic reticulum; Med, medium; ROS, reactive oxygen species.</p